Pulmonary Or Respiratory Drug Delivery Market Report 2026

Pulmonary Or Respiratory Drug Delivery Market Overview

• Pulmonary Or Respiratory Drug Delivery market size has reached to $75.67 billion in 2025 • Expected to grow to $114.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Surge In Prevalence Of Pneumonia Driving Market Growth Due To Increased Need For Effective Respiratory Treatment Delivery • Market Trend: Innovations In Complex Drug Delivery Systems Revolutionizing Pulmonary And Respiratory Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pulmonary Or Respiratory Drug Delivery Market?

Pulmonary or respiratory drug delivery refers to the administration of medication directly into the lungs to achieve rapid absorption, targeted treatment, and reduced systemic side effects for both local and systemic therapeutic effects. The main product types of pulmonary or respiratory drug delivery are formulation type and device type. Formulation type refers to the preparation method used to administer drugs effectively, ensuring accurate dosing and absorption in the body. The various canister types include plain canisters and coated canisters. These are used for various applications such as chronic obstructive pulmonary disease, asthma, cystic fibrosis, and other conditions. These are also used for various end-users such as hospitals, clinics, and home care settings.

What Is The Pulmonary Or Respiratory Drug Delivery Market Growth Forecast?

The pulmonary or respiratory drug delivery market size is expected to see strong growth in the next few years. It will grow to $114.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to aging population, rising air pollution exposure, growth in digital inhalers, expansion of homecare settings, increasing chronic respiratory conditions. Major trends in the forecast period include rising adoption of inhalation-based drug delivery, increasing demand for home-based respiratory therapies, growing use of dry powder and metered dose inhalers, expansion of chronic respiratory disease management, increased focus on patient-friendly delivery devices.

Global Pulmonary Or Respiratory Drug Delivery Market Segmentation

1) By Product: Formulation Type, Device Type 2) By Canister Type: Plain Canister, Coated Canister 3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications 4) By End-User: Hospitals, Clinics, Home Care Settings Subsegments: 1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays 2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

What Is The Driver Of The Pulmonary Or Respiratory Drug Delivery Market?

The increasing prevalence of pneumonia is expected to propel the growth of the pulmonary or respiratory drug delivery market going forward. Pneumonia is a lung infection that causes inflammation of the air sacs, which may fill with fluid or pus, leading to symptoms like cough, fever, and difficulty breathing. The rising prevalence of pneumonia such as aging populations, weakened immune systems, respiratory infections, air pollution, smoking, and the rise of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery helps pneumonia patients by directly targeting the lungs with medications, such as antibiotics, bronchodilators, or anti-inflammatory agents, enabling faster and more effective treatment to alleviate symptoms, reduce inflammation, clear infections, and improve respiratory function, ultimately enhancing recovery and preventing complications. For instance, in December 2024, according to Clinical Trials Arena, a UK-based clinical research news platform, hospital admissions of Mycoplasma pneumoniae increased by 461% from October 2023 to February 2024, rising from 110 to 617 admissions, with 20.2% of pneumonia cases detected in children aged 0 to 4 years, 25.4% in children aged 5 to 9 years, and 17.5% in children aged 10 to 14 years, contributing 410 of the 650 cases reported. Therefore, the increasing prevalence of pneumonia drives the pulmonary or respiratory drug delivery industry.

Key Players In The Global Pulmonary Or Respiratory Drug Delivery Market

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Global Pulmonary Or Respiratory Drug Delivery Market Trends and Insights

Major companies operating in the pulmonary or respiratory drug delivery market are focusing on technological advancements such as complex drug delivery systems that enhance treatment efficacy and patient compliance. Complex drug delivery systems are advanced technologies that enhance the targeted delivery and controlled release of therapeutic agents, improving drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company that manufactures generic and branded medicines and Kindeva Drug Delivery L.P., a US-based company that offers drug delivery launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol approved by the Food and Drug Administration, a US-based government agency. This is the first generic version of AstraZeneca's Symbicort and a metered-dose inhaler that combines budesonide and formoterol for treating asthma and chronic obstructive pulmonary disease. It is available in two strengths of 80 micrograms and 160 micrograms with 4.5 micrograms of formoterol.

What Are Latest Mergers And Acquisitions In The Pulmonary Or Respiratory Drug Delivery Market?

In January2025, Molex LLC, a US-based electronic solutions provider and parent company to Phillips-Medisize, acquired Vectura Group Ltd., for an undisclosed amount. Through this acquisition, Molex aims to enhance Phillips-Medisize’s pulmonary and respiratory drug delivery offerings by integrating Vectura’s advanced inhalation device technologies, enabling development of next-generation inhalation therapies and expanding its global product portfolio. Vectura Group Ltd. is a UK-based provider of inhalation drug deliver0.0y systems with a strong track record in respiratory therapy device innovation.

Regional Insights

North America was the largest region in the pulmonary or respiratory drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pulmonary Or Respiratory Drug Delivery Market?

The pulmonary or respiratory drug delivery market consists of sales of metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, aerosol formulations, and smart inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pulmonary Or Respiratory Drug Delivery Market Report 2026?

The pulmonary or respiratory drug delivery market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary or respiratory drug delivery industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.